Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Publication year range
1.
J Enzyme Inhib Med Chem ; 32(1): 240-247, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28097896

ABSTRACT

CONTEXT: The nitrobezoxadiazole derivative NBDHEX is a potent inhibitor of glutathione transferase P1-1 (GSTP1-1) endowed with outstanding anticancer activity in different tumor models. OBJECTIVE: To characterize by in vitro biochemical and in silico studies the NBDHEX analogues named MC2752 and MC2753. MATERIALS AND METHODS: Synthesis of MC2752 and MC2753, biochemical assays and in silico docking and normal-mode analyses. RESULTS: The presence of a hydrophobic moiety in the side chain of MC2753 confers unique features to this molecule. Unlike its parent drug NBDHEX, MC2753 does not require GSH to trigger the dissociation of the complex between GSTP1-1 and TRAF2, and displays high stability towards the nucleophilic attack of the tripeptide under physiological conditions. DISCUSSION AND CONCLUSION: MC2753 may represent a lead compound for the development of novel GSTP1-1 inhibitors not affected in their anticancer action by fluctuations of cellular GSH levels, and characterized by an increased half-life in vivo.


Subject(s)
Enzyme Inhibitors/pharmacology , Glutathione S-Transferase pi/antagonists & inhibitors , Oxazoles/pharmacology , Cell Line, Tumor , Enzyme Inhibitors/chemistry , Enzyme-Linked Immunosorbent Assay , Humans , Models, Molecular , Oxazoles/chemistry , Spectrometry, Fluorescence , Spectrophotometry, Ultraviolet
2.
Cancer Sci ; 104(2): 223-30, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23121163

ABSTRACT

Malignant pleural mesothelioma is a poorly responsive tumor known to overexpress the phase II detoxification enzyme glutathione-S-transferase, which catalyzes the conjugation between glutathione and platinum(II)-containing drugs. Therefore, we evaluated the effect of the strong glutathione S-transferase inhibitor NBDHEX on human mesothelioma cell lines (MSTO-211H, MPP89, MM-B1 and Mero 48a) featuring the most common mesothelioma phenotypes: epithelioid and biphasic. Even though a different response to NBDHEX was observed, the molecule was very effective on all cell lines tested, triggering a sustained activation of both JNK and p38, followed by caspase activation and apoptosis. NBDHEX also caused severe oxidative stress in the MPP89 cells and, to a lesser extent, in the MMB1 cells, while it did not cause a significant redox imbalance in the other cell lines. The efficacy of the drug was found to be comparable or even higher than that of cisplatin. Moreover, it showed synergistic or additive effects when used in combination with cisplatin. In conclusion, NBDHEX was effective on mesothelioma cell lines, with IC(50) values in the low micromolar range (IC(50) between 1 and 4 µM). These findings indicate that NBDHEX, alone or in combination with cisplatin, is a promising new strategy for treating this rare and aggressive malignancy.


Subject(s)
Glutathione S-Transferase pi/antagonists & inhibitors , Mesothelioma/drug therapy , Mesothelioma/enzymology , Oxadiazoles/pharmacology , Pleural Neoplasms/drug therapy , Pleural Neoplasms/enzymology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Apoptosis/drug effects , Caspases/metabolism , Cell Death/drug effects , Cell Line, Tumor , Cisplatin/administration & dosage , Drug Synergism , Glutathione/metabolism , Glutathione Disulfide/metabolism , Glutathione S-Transferase pi/metabolism , Humans , Inhibitory Concentration 50 , MAP Kinase Kinase 4/metabolism , MCF-7 Cells , Mesothelioma/metabolism , Mitogen-Activated Protein Kinase Kinases/metabolism , Molecular Targeted Therapy , Oxadiazoles/administration & dosage , Oxadiazoles/adverse effects , Pleural Neoplasms/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
3.
J Biol Chem ; 280(51): 42172-80, 2005 Dec 23.
Article in English | MEDLINE | ID: mdl-16195232

ABSTRACT

We have recently shown that dinitrosyl diglutathionyl iron complex, a possible in vivo nitric oxide (NO) donor, binds with extraordinary affinity to one of the active sites of human glutathione transferase (GST) P1-1 and triggers negative cooperativity in the neighboring subunit of the dimer. This strong interaction has also been observed in the human Mu, Alpha, and Theta GST classes, suggesting a common mechanism by which GSTs may act as intracellular NO carriers or scavengers. We present here the crystal structure of GST P1-1 in complex with the dinitrosyl diglutathionyl iron ligand at high resolution. In this complex the active site Tyr-7 coordinates to the iron atom through its phenolate group by displacing one of the GSH ligands. The crucial importance of this catalytic residue in binding the nitric oxide donor is demonstrated by site-directed mutagenesis of this residue with His, Cys, or Phe residues. The relative binding affinity for the complex is strongly reduced in all three mutants by about 3 orders of magnitude with respect to the wild type. Electron paramagnetic resonance spectroscopy studies on intact Escherichia coli cells expressing the recombinant GST P1-1 enzyme indicate that bacterial cells, in response to NO treatment, are able to form the dinitrosyl diglutathionyl iron complex using intracellular iron and GSH. We hypothesize the complex is stabilized in vivo through binding to GST P1-1.


Subject(s)
Ferrous Compounds/metabolism , Glutathione S-Transferase pi/metabolism , Nitric Oxide Donors/metabolism , Base Sequence , Binding Sites , DNA Primers , Ferrous Compounds/chemistry , Glutathione/analogs & derivatives , Glutathione S-Transferase pi/chemistry , Humans , Kinetics , Models, Molecular , Mutagenesis, Site-Directed , Nitric Oxide Donors/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL